Opendata, web and dolomites

MYODM-FSMP SIGNED

New food for special medical purposes to nutritionally manage Myotonic Dystrophy type 1

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYODM-FSMP project word cloud

Explore the words cloud of the MYODM-FSMP project. It provides you a very rough idea of what is the project "MYODM-FSMP" about.

food    quality    sponsored    rights    life    faces    fsmp    leave    worldwide    overcome    human    people    wo2016075288    awarded    special    advantages    barrier    treatment    trial    wo2016075285    competitive    community    broadly    gain    cohort    de    effect    cure    patients    medical    supplements    intended    commitment    claim    citizens    neurologist    launching    neuromuscular    suffer    supplement    acute    either    15    drugs    purpose    certain    disease    feasibility    a1    commercially    methylxanthines    first    som    dystrophy    company    upgrade    individuals    licensee    evidences    2017    myotonic    sustainable    dm1    small    dr    associations    pilot    munain    million    owning    consume    rare    pez    foods    launched    intellectual    clinical       leaded    disclosed    neurologists    multisystemic    behind    adolfo    goals    oacute    patient    data    soe    dietary    specialized    prescribe    myodm    confidence    property    option    diseases    patents    myogem    perform    solution    ends    market    compile    light    purposes   

Project "MYODM-FSMP" data sheet

The following table provides information about the project.

Coordinator
MYOGEM HEALTH COMPANY SL 

Organization address
address: C/ALVAREZ DE CASTRO, 63
city: MOLLET DEL VALLES
postcode: 8100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MYOGEM HEALTH COMPANY SL ES (MOLLET DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Myotonic Dystrophy type 1 (DM1) is the most common and multisystemic neuromuscular rare disease affecting 1 million people worldwide, 100,000 EU citizens, who still have no cure or treatment available. In the light of the ´Leave No-one Behind´ commitment behind Sustainable Development Goals and particularly, the dietary management approach may provide a unique option for rare disease patients through Foods for special medical purposes (FSMP), foods (not drugs) intended for the dietary management of individuals who suffer from certain diseases. The main goal of the present project is to compile in human evidences that MYODM’s food for special medical purposes is a unique approach to improve DM1 patients’ Quality of Life through a pilot clinical trial for foods and supplements sponsored by Myogem and leaded by Dr. Adolfo López de Munain, a worldwide neurologist specialized in DM1. MYOGEM is the current licensee of the patents WO2016075288 A1 and WO2016075285 A1, which disclosed the effects of some methylxanthines on DM1. Owning the Intellectual Property Rights over the present solution is one of the main competitive advantages of MYOGEM. MYOGEM is the first and unique company worldwide who launched a food supplement for a rare disease in May 2017. However, as food supplement MYODM faces the problem that DM1 community, either neurologists and patient associations, claim for in human data in order to broadly prescribe and consume the product. To overcome this barrier, and gain market confidence, MYOGEM aims to perform a Feasibility pilot clinical trial to demonstrate MYODM’s effect on a small cohort of 10-15 DM1 patients in order to commercially upgrade our current product “food supplement” to “food for special medical purpose”, from now on referred as MYODM-FSMP, that will reach the market in less than one year after the present project ends. By launching the new MYODM-FSMP product, a 5.5 M€ SOM is expected in 5 years after the project. Two SoE have been awarded.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYODM-FSMP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYODM-FSMP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More